Karin Borgmann-Winter

Karin Borgmann-Winter, MD, MS

Contact Dr. Borgmann-Winter

Bluemle Life Sciences Building
233 S 10th St, Room 226
Philadelphia, PA 19107

215-955-6744

Most Recent Peer-reviewed Publications

  1. mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia
  2. The proteome and its dynamics: A missing piece for integrative multi-omics in schizophrenia
  3. Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease
  4. Sociability Deficits and Altered Amygdala Circuits in Mice Lacking Pcdh10, an Autism Associated Gene
  5. The PSD: A Microdomain for Converging Molecular Abnormalities in Schizophrenia
  6. Effects of sex and DTNBP1 (dysbindin) null gene mutation on the developmental GluN2B-GluN2A switch in the mouse cortex and hippocampus
  7. Altered g protein coupling in olfactory neuroepithelial cells from patients with schizophrenia
  8. Molecular evidence for decreased synaptic efficacy in the postmortem olfactory bulb of individuals with schizophrenia
  9. Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia
  10. Translational potential of olfactory mucosa for the study of neuropsychiatric illness
  11. Pyramidal cell selective ablation of N-methyl-D-aspartate receptor 1 causes increase in cellular and network excitability
  12. Facial emotion perception differs in young persons at genetic and clinical high-risk for psychosis
  13. Olfactory processing in schizophrenia, non-ill first-degree family members, and young people at-risk for psychosis
  14. Increased stability of microtubules in cultured olfactory neuroepithelial cells from individuals with schizophrenia
  15. Is prevention a realistic goal for schizophrenia?
  16. Meta-analysis of olfactory function in schizophrenia, first-degree family members, and youths at-risk for psychosis
  17. The effect of odor valence on olfactory performance in schizophrenia patients, unaffected relatives and at-risk youth
  18. Attention-deficit/hyperactivity disorder genomics: Update for clinicians
  19. An odor-specific threshold deficit implicates abnormal cAMP signaling in youths at clinical risk for psychosis
  20. Evaluation and treatment of children and adolescents with psychotic symptoms
  21. Epigenetics: Genetics versus life experiences
  22. Computerized neurocognitive profile in young people with 22q11.2 deletion syndrome compared to youths with schizophrenia and At-Risk for psychosis
  23. Methylphenidate transdermal system: Clinical applications for attention-deficit/hyperactivity disorder
  24. Neuregulin 1-erbB4 pathway in schizophrenia: From genes to an interactome
  25. Use of metformin to control clozapine-associated weight gain in an adolescent with schizoaffective disorder